Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Assets (2016 - 2025)

Historic Current Assets for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $246.5 million.

  • Summit Therapeutics' Current Assets fell 4973.06% to $246.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.5 million, marking a year-over-year decrease of 4973.06%. This contributed to the annual value of $423.8 million for FY2024, which is 12336.49% up from last year.
  • Summit Therapeutics' Current Assets amounted to $246.5 million in Q3 2025, which was down 4973.06% from $309.2 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Current Assets registered a high of $656.7 million during Q4 2022, and its lowest value of $79.4 million during Q2 2022.
  • Moreover, its 5-year median value for Current Assets was $205.0 million (2023), whereas its average is $243.2 million.
  • In the last 5 years, Summit Therapeutics' Current Assets skyrocketed by 57485.2% in 2022 and then plummeted by 7111.18% in 2023.
  • Quarter analysis of 5 years shows Summit Therapeutics' Current Assets stood at $97.3 million in 2021, then skyrocketed by 574.85% to $656.7 million in 2022, then crashed by 71.11% to $189.7 million in 2023, then skyrocketed by 123.36% to $423.8 million in 2024, then tumbled by 41.84% to $246.5 million in 2025.
  • Its Current Assets was $246.5 million in Q3 2025, compared to $309.2 million in Q2 2025 and $370.8 million in Q1 2025.